Health
Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): Interim results of a randomized, double-blind, controlled, phase 3 trial – MD Linx
MDLinx original journal summary on Vaccines, Internal Medicine from The Lancet
Findings demonstrate the high efficacy of BBV152, a whole virion inactivated SARS-CoV-2 vaccine formulated with a toll-like receptor 7/8 agonist molecule adsorbed to alum (Algel-IMDG), in preventing laboratory-confirmed symptomatic COVID-19 disease in adults….
Continue Reading
-
Business24 hours agoIs Warren Buffett’s Berkshire Hathaway the smartest investment you can make today?
-
Noosa News10 hours agoCommissioner thanks police officer who threw a speed radar at a car
-
General24 hours agoTaiwan’s President Lai Ching-te calls for peace and dialogue with China while also calling for defence boosts
-
Noosa News18 hours agoCountdown on for Noosa Eat & Drink Festival 2025